Summary & Overview
HCPCS C7550: Cystourethroscopy with Biopsy Using Blue Light Fluorescent Imaging
HCPCS Level II code C7550 represents cystourethroscopy with biopsy(ies) using adjunctive blue light cystoscopy and a fluorescent imaging agent. This code captures an advanced diagnostic and minor interventional urologic procedure that pairs endoscopic visualization with fluorescence-guided detection to improve identification of abnormal bladder or urethral tissue. Its national relevance stems from growing adoption of enhanced imaging techniques to improve diagnostic yield, guide biopsy targeting, and potentially affect downstream management decisions.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for C7550, common settings where the procedure is performed, and the types of benchmarks and policy elements typically associated with adoption of fluorescence-guided cystoscopy. The publication outlines expected service lines, typical sites of service, and which clinical workflows are implicated by use of an adjunctive imaging agent.
The report also summarizes payer coverage patterns, billing considerations, and typical modifier usage where available. Benchmarks include utilization trends and reimbursement considerations when provided by payers. Policy updates and clinical context address how adoption of blue light cystoscopy with fluorescent agents fits within contemporary urologic diagnostic pathways. Data not available in the input is noted as such where applicable.
Billing Code Overview
HCPCS Level II code C7550 describes cystourethroscopy with biopsy(ies) performed using adjunctive blue light cystoscopy with a fluorescent imaging agent. This procedure combines standard endoscopic visualization of the bladder and urethra with a targeted biopsy and the use of a fluorescent imaging agent under blue light to enhance detection of abnormal tissue.
Service type: Diagnostic/interventional endoscopic urologic procedure with targeted biopsy and enhanced imaging
Typical site of service: Hospital outpatient department, ambulatory surgery center, or specialized urology clinic with endoscopy capability
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old male with a history of non–muscle-invasive bladder cancer who presents for surveillance cystoscopy after prior transurethral resection of bladder tumor (TURBT). During the clinic visit the urologist documents recurrent microscopic hematuria and prior pathology showing papillary urothelial carcinoma. The planned procedure is diagnostic and therapeutic: C7550 (cystourethroscopy with biopsy(ies) with adjunctive blue light cystoscopy using a fluorescent imaging agent) performed in an ambulatory surgical center or hospital outpatient department under monitored anesthesia care or general anesthesia.
Preoperative workflow includes medication reconciliation, informed consent specific to fluorescent agent administration, allergy assessment (noting any photosensitizer sensitivities), and verification of prior pathology and imaging. Intraoperative steps include instillation of the approved fluorescent imaging agent into the bladder per manufacturer instructions, a dwell time to permit tumor uptake, inspection of the bladder under white light followed by blue light/fluorescent imaging to identify occult lesions, targeted cold-cup or transurethral biopsy of suspicious areas, hemostasis, and specimen submission to pathology. Postoperative workflow includes recovery monitoring for urinary retention or hematuria, discharge instructions, and pathology-driven follow-up planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |